New combo therapy aims to shrink cervical tumors
NCT ID NCT06266338
First seen Jan 10, 2026 · Last updated May 25, 2026 · Updated 22 times
Summary
This study tests whether two drugs, pembrolizumab and lenvatinib, can slow tumor growth in people with cervical cancer that has come back or spread. About 30 adults with certain types of cervical cancer will receive the combination. The goal is to see if the treatment shrinks or stabilizes the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.